Target Information

Target General Infomation
Target ID
T06421
Former ID
TTDS00492
Target Name
Interferon-alpha/beta receptor
Gene Name
IFNAR2
Synonyms
IFN-R; IFN-alpha-REC; Interferon alpha/beta receptor; Type I interferon receptor; IFNAR2
Target Type
Successful
Disease Advanced renal cell carcinoma [ICD9: 189; ICD10: C64]
Endometriosis [ICD9: 617; ICD10: N80]
Hairy cell leukemia, malignant melanoma; Chronic myelogenous leukaemia [ICD9:172, 202.4, 208.9, 205.1; ICD10: C43, C91-C95, C91.4, C92.1]
Hairy cell leukemia; HCV infection [ICD9:202.4, 070.4, 070.5, 070.70; ICD10: C91.4, B17.1, B18.2]
Hairy cell leukemia [ICD9: 202.4; ICD10: C91.4]
Multiple scierosis [ICD9: 340; ICD10: G35]
Systemic lupus erythematosus; Myositis [ICD9: 695, 710.0, 729.1; ICD10: L51-L54, M32, M60]
Function
Receptor forinterferons alpha and beta. Isoform 1 and isoform 3 are directly involved in signal transduction due to their interaction with the tyr kinase, jak1. Isoform 1 also interacts with the transcriptional factors, stat1 and stat2. Both forms are potent inhibitors of type i ifn activity.
BioChemical Class
Type II cytokine receptor
UniProt ID
P48551
Sequence
MLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS
IVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF
SCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK
HKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE
SAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD
MVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI
DPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR
ITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT
FPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR
Drugs and Mode of Action
Drug(s) Interferon Alfa-2b, Recombinant Drug Info Approved Hairy cell leukemia [536361]
Interferon alfa-n1 Drug Info Approved Hairy cell leukemia, malignant melanoma; Chronic myelogenous leukaemia [536361], [551871]
Interferon alfacon-1 Drug Info Approved Hairy cell leukemia; HCV infection [536361], [551871]
Interferon beta-1b Drug Info Approved Multiple scierosis [536361]
Sifalimumab Drug Info Approved Advanced renal cell carcinoma [529282], [543015]
Sifalimumab Drug Info Phase 2 Systemic lupus erythematosus; Myositis [543015], [551134]
Alfa-interferon Drug Info Phase 1 Endometriosis [530984]
Stimulator Alfa-interferon Drug Info [536772]
Binder Interferon Alfa-2b, Recombinant Drug Info [537218]
Interferon alfa-n1 Drug Info [535821], [538052], [538094]
Interferon alfacon-1 Drug Info [537155]
Interferon beta-1b Drug Info [537596]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Cytokine-cytokine receptor interaction
PI3K-Akt signaling pathway
Osteoclast differentiation
Toll-like receptor signaling pathway
Jak-STAT signaling pathway
Natural killer cell mediated cytotoxicity
Hepatitis C
Hepatitis B
Measles
Influenza A
Herpes simplex infection
Reactome Interferon alpha/beta signaling
Regulation of IFNA signaling
WikiPathways Toll-like receptor signaling pathway
Interferon type I signaling pathways
Interferon alpha/beta signaling
Regulation of toll-like receptor signaling pathway
Osteoclast Signaling
References
Ref 5292822007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
Ref 530984A phase I trial of alpha-interferon in combination with pentostatin in hematologic malignancies. Med Pediatr Oncol. 1991;19(4):276-82.
Ref 536361Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20.
Ref 543015(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8257).
Ref 551134Clinical pipeline report, company report or official report of MedImmune (2011).
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 535821The clinical application of the interferons: a review. NSW Therapeutic Assessment Group. Med J Aust. 1992 Jun 15;156(12):869-72.
Ref 536772New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202.
Ref 537155Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology. 2009 Jun;49(6):1838-46.
Ref 537218Successful treatment of relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia with T315I mutation after haplo-identical hematopoietic stem cell transplantation with donor lymphocyte transfusion and interferon-alpha-2b. Leuk Res. 2009 Aug;33(8):e111-3. Epub 2009 Apr 10.
Ref 537596Interferon-beta(1b) Treatment in Neuromyelitis Optica. Eur Neurol. 2009 Jul 7;62(3):167-170.
Ref 538052Therapy of hepatitis C: interferon alfa-n1 trials. Hepatology. 1997 Sep;26(3 Suppl 1):96S-100S.
Ref 538094Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study. Hepatology. 1998 Apr;27(4):1121-7.
Ref 550288Clinical pipeline report, company report or official report of AstraZeneca (2009).
Ref 551134Clinical pipeline report, company report or official report of MedImmune (2011).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.